Kymera Accelerates Phase 2b Data Timeline for Oral Dermatitis Treatment

Kymera Therapeutics is accelerating the development of its oral immunology pipeline by moving the expected data readout for its Phase 2b atopic dermatitis study, BROADEN2, to the end of 2026. This adjustment moves the timeline up from the company's previously scheduled mid-2027 target for its lead candidate, KT-621.

"We want to build a commercial global biopharma company that can do innovation and deliver what patients are looking for, which are effective oral drugs. That is our mission," said Nello Mainolfi, Kymera’s president and chief executive, during the Wells Fargo healthcare conference.

Clinical Progress for KT-621

KT-621 is an oral STAT6 degrader designed to treat inflammatory conditions. According to a company transcript, the drug has been administered to approximately 200 subjects in clinical settings, including both healthy volunteers and patients. The company reported that no serious adverse events have been observed in these trials to date.

Kymera is positioning the oral degrader as an alternative to injectable biologics, which have long dominated the market for atopic dermatitis treatments. By targeting the STAT6 pathway, the company aims to achieve clinical outcomes that match the efficacy of existing monoclonal antibody therapies.

"There is very reasonable grounds to expect scientifically that pathway blockade would be [comparable to biologics]," said Terence Rooney, Kymera’s chief medical officer.

Strategic Shift Toward Oral Delivery

The acceleration of the BROADEN2 trial reflects Kymera's strategic pivot toward oral delivery mechanisms. While many immunology treatments rely on complex, intravenous or subcutaneous administration, the company is prioritizing oral small-molecule degraders to improve patient convenience and reduce the logistical burdens associated with clinical-site-administered biologics.

This development is important for Kymera as it attempts to transition from a research-focused organization into a commercial-stage biopharmaceutical firm. By pulling forward the data readout, the company aims to provide earlier clarity on the drug's efficacy profile to support its commercialization strategy.